3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
11
Endocrine
11
Thoracic
4
Gynecologic
4
Gastrointestinal
2
Plasma cell
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Multiple Myeloma
495
Lymphoma
52
Recurrence
50
Neoplasms, Plasma Cell
49
Immunoglobulin Light-chain Amyloidosis
43
Neoplasms
35
Lymphoma, Non-Hodgkin
35
Leukemia
34
Hematologic Neoplasms
32
Myelodysplastic Syndromes
28
Smoldering Multiple Myeloma
27
Leukemia, Myeloid, Acute
26
Leukemia, Plasma Cell
23
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Monoclonal Gammopathy of Undetermined Significance
18
Hodgkin Disease
18
Leukemia, Lymphocytic, Chronic, B-Cell
17
Amyloidosis
17
Lymphoma, B-Cell
15
Breast Neoplasms
14
Ovarian Neoplasms
12
Paraproteinemias
11
Myeloproliferative Disorders
10
Colorectal Neoplasms
10
Primary Myelofibrosis
9
Melanoma
9
Lymphoma, Follicular
9
Infections
9
Prostatic Neoplasms
8
Lymphoproliferative Disorders
8
Interventions
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Thyroid Carcinoma, Anaplastic
×
Plasma cell
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled